Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa

David Marin, Sarah Marktel, Richard Szydlo, John P. Klein, Marco Bua, Nicola Foot, Eduardo Olavarria, Pat Shepherd, Edward Kanfer, John M. Goldman, Jane F. Apperley

Research output: Contribution to journalArticle

Abstract

Until the recent introduction of imatinib, interferon alfa was the standard treatment for patients in the chronic phase of chronic myeloid leukaemia. We compared survival of 143 such patients, who did not respond to interferon alfa and were treated with imatinib, with that of 246 historical controls who received conventional treatment. Patients on imatinib showed an overall survival advantage (relative risk 0.54, 95% CI 0.31-0.93). However, although patients on imatinib who achieved at least some degree of cytogenetic response after 6 months had better survival than controls (0.13, 0.05-0.39), those with no cytogenetic response to imatinib had significantly worse survival (1.69, 1.09-2.64). Our findings suggest that cytogenetic responders obtain benefit from imatinib but patients who show no cytogenetic response should be given alternative treatment without delay. We confirmed these results in a case-matched analysis.

Original languageEnglish
Pages (from-to)617-619
Number of pages3
JournalLancet
Volume362
Issue number9384
DOIs
Publication statusPublished - Aug 23 2003

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa'. Together they form a unique fingerprint.

  • Cite this

    Marin, D., Marktel, S., Szydlo, R., Klein, J. P., Bua, M., Foot, N., Olavarria, E., Shepherd, P., Kanfer, E., Goldman, J. M., & Apperley, J. F. (2003). Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa. Lancet, 362(9384), 617-619. https://doi.org/10.1016/S0140-6736(03)14182-7